Processa Pharmaceuticals Announces First Patient Enrolled in the PCS12852 Phase 2A Trial for the Treatment of Gastroparesis
05 avr. 2022 08h30 HE
|
Processa Pharmaceuticals, Inc.
Study will advance understanding of proper dosing while providing data to assist in the design of the next study for this >$1B marketExpect top line data at the end of 2022 HANOVER, MD, April ...